{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001437402","name":"ARDELYX, INC.","summary":"Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines. It markets two FDA-approved therapies based on tenapanor, an NHE3 inhibitor: IBSRELA for irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company also has a pipeline including a Phase 3 trial for CIC and a next-generation NHE3 inhibitor program (RDX10531).","people":[],"products":[{"name":"IBSRELA (tenapanor)","type":"service","description":"FDA-approved NHE3 inhibitor for treatment of IBS-C in adults; first U.S. sales in March 2022."},{"name":"XPHOZAH (tenapanor)","type":"service","description":"FDA-approved phosphate absorption inhibitor to reduce serum phosphorus in adults with CKD on dialysis; first U.S. sales in December 2023."},{"name":"RDX10531","type":"service","description":"Next-generation NHE3 inhibitor in preclinical development with potential application across multiple therapeutic areas; IND submission planned second half of 2026."}],"partnerships":[{"partner_name":"Knight","partnership_type":"licensing","description":"Exclusive license for development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C.","start_date":null},{"partner_name":"Kyowa Kirin","partnership_type":"licensing","description":"Exclusive license for development, commercialization and distribution of tenapanor in Japan for cardiorenal indications; PHOZEVEL launched February 2024.","start_date":null},{"partner_name":"Fosun Pharma","partnership_type":"licensing","description":"Exclusive license for development and commercialization of tenapanor in China for hyperphosphatemia and IBS-C; NDA approved February 2025.","start_date":null},{"partner_name":"METiS","partnership_type":"licensing","description":"Exclusive license for development and commercialization of a portfolio of TGR5 agonist compounds for all therapeutic areas.","start_date":null},{"partner_name":"HCR","partnership_type":"strategic","description":"Agreement covering sale of future royalties and commercialization milestones; future royalties from Kyowa Kirin license remitted to HCR.","start_date":null},{"partner_name":"SLR","partnership_type":"strategic","description":"Loan and security agreement (2022 Loan Agreement) providing up to $300 million in financing, with $200 million drawn and outstanding.","start_date":null},{"partner_name":"Jefferies","partnership_type":"strategic","description":"At-the-market offering sales agent under 2023 and 2025 Open Market Sales Agreements; up to $100 million under 2025 agreement.","start_date":null}],"affiliations":[],"origin":{"leaf":"a8c9bda8b6baaafafa65e2c90f1d30e5c77326f9d880b9afca8dc51d0b32c1a4","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"0d560f556b82ddc710c60f1902ca3a62b736a0c52f7a5e2aabaf993df40f035d","parent":"6e84a0f7d4a91093c90ada086a7be1f54874062a6054440df58a4a8df46262f6","source":"0001437402-26-000013","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":108,"hourly_limit":500,"remaining":392,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}